About
PhotoPharmics is a pioneering biotechnology company specializing in the treatment of neurodegenerative disorders through the eyes. With over 30 years of research and experience, the company has developed advanced light-based therapies that regulate circadian rhythms—helping millions manage conditions like Seasonal Affective Disorder (SAD), sleep disorders, anxiety, and depression. Building on its legacy of innovation (including technology acquired by Philips-Respironics in 2007), PhotoPharmics now focuses on diseases such as Parkinson’s, where retinal deterioration and circadian disruption play key roles. Their groundbreaking research in specialized wavelengths of light has led to a pivotal clinical trial aimed at reducing Parkinson’s symptoms, with results anticipated for publication in Autumn 2018.
Lehi